ClinicalTrials.gg
CompletedNCT00756509Updated Jul 16, 2026Results posted

Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib

A Phase 4 interventional study of Nilotinib in Gastrointestinal Stromal Tumors, sponsored by Novartis Pharmaceuticals. Completed at 10 sites in 5 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
34
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing nilotinib in Gastrointestinal Stromal Tumors — none open to participants now, none under way, none of them phase 3. nilotinib · Gastrointestinal Stromal Tumors.

Enrollment
8th of 14
34 · median 35
Started
2008
with 5 others
Phase 4
2 of 14
none open now
Registered
7th of 14
by date
Lead sponsor
12 of 14
Novartis Pharmaceuticals

Among the 14 studies testing nilotinib in Gastrointestinal Stromal Tumors, this one is the 8th largest by enrollment, is one of 6 that started in 2008, is one of 2 in phase 4, and was the 7th registered.

Gastrointestinal Stromal Tumors

343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.

Browse Gastrointestinal Stromal Tumors studies →

Open to participants now

None of the 14 studies testing nilotinib in Gastrointestinal Stromal Tumors is open now. The open studies under Gastrointestinal Stromal Tumors, anywhere →

About nilotinib

nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing nilotinib in Gastrointestinal Stromal Tumors as a file.
02

Study summary

The purpose of this multicenter, single-arm, phase II trial is to evaluate the efficacy of Nilotinib in patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).

Read the detailed description

The study planned a 6-month recruitment phase to enroll 40 subjects, followed by a 6-month treatment phase with monthly visits. Patients benefiting from the treatment could continue during a follow-up phase.

On May 5, 2011, Novartis decided to discontinue the ongoing clinical trials with Nilotinib in GIST. This decision was influenced by the discontinuation of the ENESTg1 study (CAMN107G2301), which showed that Nilotinib was unlikely to demonstrate superiority to Imatinib in progression-free survival, the primary endpoint. The independent Data Management Committee (DMC) also reported no safety issues in either trial arm. Following the decision to close-out the Novartis- Sponsored studies CAMN107G2301 (NCT00785785) and CAMN107DDE05 (NCT01289028), the enrollment of the study CAMN107DDE06 was re-opened in order to ensure continued access to nilotinib to the patients currently in the CAMN107G2301 trial and CAMN107DDE05 trial in Germany and benefiting from the nilotinib treatment.

03

Conditions studied

  • Gastrointestinal Stromal Tumors

Keywords

  • unresectable or metastatic GIST
  • 1st. line treatment
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • confirmed diagnosis of GIST that is unresectable and/or and therefore not amenable to surgery or combined modality with curative intent prior to or at Visit 1
  • At least one measurable site of disease on CT/MRI scan at Visit 1, as defined by criteria. The scans should be at maximum 2 weeks old. New scans are only required as baseline scans if they are older than approx. 2 weeks.
  • of 0, 1 or 2
  • Patients must have the following laboratory values (≥ LLN (lower limit of normal) or corrected to within normal limits with supplements prior to the first dose of study medication.):

    1. Potassium ≥ LLN,
    2. Magnesium ≥ LLN,
    3. Phosphorus ≥ LLN,
    4. Total calcium (corrected for serum albumin) ≥ LLN
  • Patients must have normal organ, electrolyte, and marrow function as defined below:

    1. (ANC) ≥ 1.5x 109/L;
    2. ≥ 100 x 109/L;
    3. and AST ≤ 2.5 x (ULN) or ≤ 5.0 x ULN if considered due to tumor;
    4. Alkaline phosphatase ≤ 2.5 x ULN unless considered due to tumor;
    5. Serum ≤ 1.5 x ULN;
    6. Serum lipase and amylase ≤ 1.5 x ULN;
    7. Serum creatinine ≤ 1.5 x ULN or 24-hour ≥ 50 ml/min. (calculated creatinine clearance using Cockroft formula is acceptable)
  • Ability to understand and willingness to sign a written

Exclusion criteria

Exclusion criteria

  • Prior treatment with nilotinib
  • Treatment with any cytotoxic and/or cytotoxic drug ≤ 4 weeks (6 weeks for nitrosurea or mitomycin C) prior to Visit 1 with the exception of imatinib targeted therapy as an therapy or imatinib in treatment for maximum of 4 weeks.
  • Prior or concomitant requiring active treatment other than GIST with the exception of previous or concomitant basal cell skin cancer, previous cervical carcinoma in situ
  • Impaired cardiac function at including any one of the following:

    1. \< 45% or below the institutional LLN range (whichever is higher) as determined by echocardiogram at Visit 1
    2. Complete left bundle branch block
    3. Use of a ventricular paced cardiac pacemaker
    4. Congenital long syndrome or family history of long QT syndrome
    5. History of or presence of significant ventricular or atrial tachyarrhythmias
    6. resting bradycardia (\< 50 beats per minute)
    7. QTc > 450 msec on screening (using the QTcF formula). If QTc > 450 msec and electrolytes are not within normal ranges (electrolytes should be corrected and then the patient rescreened for QTc.
    8. Right bundle branch block plus left anterior hemiblock, bifascicular block
    9. Myocardial infarction within 12 months prior to Visit 1
    10. Other clinically significant heart disease (e.g., unstable angina, congestive heart failure or uncontrolled hypertension,)
  • Patients with severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol e.g. impairment of gastrointestinal (GI) function, or GI disease that may significantly alter the absorption of the study drugs, uncontrolled diabetes
  • Use of therapeutic coumarin derivatives (i.e. warfarin, acenoucumarol, phenprocoumon)
  • Use of any medications that prolong the QT interval and inhibitors if the treatment cannot be either safely discontinued or switched to a different medication prior to starting study drug administration. Please see www.qtdrugs.org for a comprehensive list of agents that prolong the QT interval as well as [Post-Text Supplement 2].
  • Patients who have undergone major surgery ≤ 2 weeks prior to Visit 1 or who have not recovered from side effects of such surgery
  • Patients who have received wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation \< 2 weeks prior to Visit 1 or who have not recovered from side effects of such therapy
  • A history of noncompliance to medical regimens or inability or unwillingness to return for scheduled visits
  • Patients who are pregnant, breast feeding or women of (WOCBP). women must be amenorrheic for at least 12 months to be considered of non-childbearing potential Women of , to include female partners of heterosexual or bisexual patients, must agree to use an effective method of during the study and for up to three months following termination of the study.
  • Patients unwilling or unable to comply with the protocol

Eligibility criteria for patients from studies CAMN107G2301 or CAMN107DDE05 Patients currently participating in the Novartis-sponsored studies CAMN107G2301 or CAMN107DDE05 and benefiting from the nilotinib treatment according to the investigator will be offered the possibility to continue treatment with nilotinib in study CAMN107DDE06.

They will be included in study CAMN107DDE06 if the following criteria are fulfilled:

  • Patient has an confirmed diagnosis of GIST that is unresectable and/or
  • Patient is currently enrolled in the studies CAMN107G2301 or CAMN107DDE05 in Germany and is on treatment with nilotinib
  • Patient is currently benefiting from the treatment with nilotinib, as determined by the investigator
  • Patient has demonstrated compliance, as assessed by the investigator, within the CAMN107G2301 or CAMN107DDE05 protocols requirements
  • Patient has willingness and ability to comply with scheduled visits, treatment plans and any other study procedures
  • Written obtained prior to enrollment in the study
  • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
  • Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 30 days of study medication. Highly effective contraception methods include:
  • Total abstinence (when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception

    • Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
    • Male sterilization (at least 6 months prior to screening). For female subjects on the study the vasectomized male partner should be the sole partner for that subject.
    • Combination of any two of the following (a+b or a+c, or b+c):

      1. Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate \<1%), for example hormone vaginal ring or transdermal hormone contraception.
      2. Placement of an intrauterine device (IUD) or intrauterine system (IUS)
      3. Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository

In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment.

  • Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.
  • Sexually active males unless they use a condom during intercourse while taking drug and for 30 days after stopping study medication and should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    nilotinib

    nilotinib

    Drug: Nilotinib

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of Participants With Best Overall Response at Month 6 (Core Phase) Determined According to the RECIST v1.0.

    The primary efficacy measure is the proportion of patients reaching Complete Response (CR), Partial Response (PR), or Stable Disease (SD) by Month 6, as per RECIST v1.0. Definitions are as follows: CR requires at least two CRs at least four weeks apart before any progression; PR requires two or more PRs at least four weeks apart, without qualifying for CR; SD is at least one SD more than six weeks after treatment start, not qualifying for CR or PR. Progressive Disease (PD) is defined as progression or cancer-related death within 12 weeks of starting treatment, not qualifying for CR, PR, or SD. UNK refers to cases not meeting these criteria, such as absence of confirmed CR/PR, no SD after six weeks, or early progression. The percentage of patients with CR, PR, or SD will be presented with a one-sided exact 90% (or 80% two-sided) confidence interval for the ITT\_F group.

    Time frame: from baseline to month 6, core phase

Secondary outcomes

  1. Proportion of Participants With Objective Response Rate (ORR) at Month 6 (Core Phase) Observed According to RECIST

    Objective Response Rate (ORR) is defined as the proportion of patients in whom a complete (CR) or partial (PR) response was observed according to RECIST at month 6.

    Time frame: from baseline to month 6, core phase

  2. Time to Response (TTR) at Month 6 (Core Phase)

    Time to response is defined as the time from start of treatment to the first objective tumor response (PR or CR) observed. Patients who did not achieve a confirmed PR or CR will be censored at last adequate tumor assessment date when they did not progress (including deaths not due to underlying disease).

    Time frame: from baseline to month 6, core phase

  3. Duration of Response (CR or PR) for Complete Study (Core and Follow-up Phases)

    Duration of response is defined as the time from onset of response (CR/PR) to objective tumor progression or death from any cause. Patients not experiencing progression or death will be censored with the date of their last adequate tumor assessment.

    Time frame: from date of first response (CR or PR) until progression or death, up to data cut off (up to approximately 16 years)

  4. Progression-free Survival (PFS) for Complete Study (Core and Follow-up Phases)

    Progression-free survival (PFS) is defined as the time from first study drug administration to objective tumor progression or death from any cause. If a patient has not had an event, PFS is censored at the date of last adequate tumor assessment. PFS will be explored graphically by presenting the Kaplan-Meier curve.

    Time frame: from date of first response (CR or PR) until progression or death, up to data cut off (up to approximately 16 years)

  5. Overall Survival for Complete Study (Core and Follow-up Phases)

    Overall Survival (OS) is defined as the time from first study drug administration to death from any cause. Participants alive at their last known follow-up were censored. No deaths occurred during the study.

    Time frame: from date of first response (CR or PR) until progression or death, up to data cut off (up to approximately 16 years)

  6. Proportion of Participants With Treatment-emergent Adverse Events During the Entire Study (Core and Follow-up Phases)

    This measure summarizes the proportion of participants who experienced at least one treatment-emergent adverse event (TEAE) during the entire study period, including both core and follow-up phases. A TEAE was defined as an adverse event that began or worsened after the first dose of study treatment.

    Time frame: from the first dose through the end of the study (core and follow-up phases): including all visits up to the follow-up database lock (approximately 16 years)

07

Results

Posted Jan 20, 2026

Participant flow

Study consists of participants with unresectable or metastatic gastrointestinal stromal tumors (GIST) showing progression of disease from 5 countries: Germany, Spain, Finland, France, Italy

Core Phase
Participant flow — Core Phase
MilestoneNilotinib
Started41
Completed31
Not completed10
Withdrew: Adverse event2
Withdrew: Lack of efficacy2
Withdrew: Disease progression6
Follow-Up Phase
Participant flow — Follow-Up Phase
MilestoneNilotinib
Started31
Completed7
Not completed24
Withdrew: Missing values2
Withdrew: Disease progression9
Withdrew: Administrative problems3
Withdrew: Lost to follow-up1
Withdrew: Withdrawal by subject1
Withdrew: Subject's condition no longer requires study drug1
Withdrew: Adverse event7

Outcome measures

PrimaryProportion of Participants With Best Overall Response at Month 6 (Core Phase) Determined According to the RECIST v1.0.

The primary efficacy measure is the proportion of patients reaching Complete Response (CR), Partial Response (PR), or Stable Disease (SD) by Month 6, as per RECIST v1.0. Definitions are as follows: CR requires at least two CRs at least four weeks apart before any progression; PR requires two or more PRs at least four weeks apart, without qualifying for CR; SD is at least one SD more than six weeks after treatment start, not qualifying for CR or PR. Progressive Disease (PD) is defined as progression or cancer-related death within 12 weeks of starting treatment, not qualifying for CR, PR, or SD. UNK refers to cases not meeting these criteria, such as absence of confirmed CR/PR, no SD after six weeks, or early progression. The percentage of patients with CR, PR, or SD will be presented with a one-sided exact 90% (or 80% two-sided) confidence interval for the ITT\_F group.

Time frame:
from baseline to month 6, core phase
Reported as:
Count of participants · Participants
Proportion of Participants With Best Overall Response at Month 6 (Core Phase) Determined According to the RECIST v1.0.
ParticipantsNilotinib
Complete Response (CR)0
Partial Response (PR)14
Stable Disease (SD)21
Progressive Disease (PD)6
Unknown (UNK)0
SecondaryProportion of Participants With Objective Response Rate (ORR) at Month 6 (Core Phase) Observed According to RECIST

Objective Response Rate (ORR) is defined as the proportion of patients in whom a complete (CR) or partial (PR) response was observed according to RECIST at month 6.

Time frame:
from baseline to month 6, core phase
Reported as:
Number · Percentage of responder
Proportion of Participants With Objective Response Rate (ORR) at Month 6 (Core Phase) Observed According to RECIST
Percentage of responderNilotinib
Proportion of Participants With Objective Response Rate (ORR) at Month 6 (Core Phase) Observed According to RECIST34.1 (24.2 to 45.3)
SecondaryTime to Response (TTR) at Month 6 (Core Phase)

Time to response is defined as the time from start of treatment to the first objective tumor response (PR or CR) observed. Patients who did not achieve a confirmed PR or CR will be censored at last adequate tumor assessment date when they did not progress (including deaths not due to underlying disease).

Time frame:
from baseline to month 6, core phase
Reported as:
Median · Days
Time to Response (TTR) at Month 6 (Core Phase)
DaysNilotinib
Time to Response (TTR) at Month 6 (Core Phase)62 (57 to NA)
SecondaryDuration of Response (CR or PR) for Complete Study (Core and Follow-up Phases)

Duration of response is defined as the time from onset of response (CR/PR) to objective tumor progression or death from any cause. Patients not experiencing progression or death will be censored with the date of their last adequate tumor assessment.

Time frame:
from date of first response (CR or PR) until progression or death, up to data cut off (up to approximately 16 years)
Reported as:
Median · Days
Duration of Response (CR or PR) for Complete Study (Core and Follow-up Phases)
DaysNilotinib
Duration of Response (CR or PR) for Complete Study (Core and Follow-up Phases)2722 (588 to NA)
SecondaryProgression-free Survival (PFS) for Complete Study (Core and Follow-up Phases)

Progression-free survival (PFS) is defined as the time from first study drug administration to objective tumor progression or death from any cause. If a patient has not had an event, PFS is censored at the date of last adequate tumor assessment. PFS will be explored graphically by presenting the Kaplan-Meier curve.

Time frame:
from date of first response (CR or PR) until progression or death, up to data cut off (up to approximately 16 years)
Reported as:
Median · Days
Progression-free Survival (PFS) for Complete Study (Core and Follow-up Phases)
DaysNilotinib
Progression-free Survival (PFS) for Complete Study (Core and Follow-up Phases)2833 (791 to NA)
SecondaryOverall Survival for Complete Study (Core and Follow-up Phases)

Overall Survival (OS) is defined as the time from first study drug administration to death from any cause. Participants alive at their last known follow-up were censored. No deaths occurred during the study.

Time frame:
from date of first response (CR or PR) until progression or death, up to data cut off (up to approximately 16 years)
Reported as:
Mean · years
Overall Survival for Complete Study (Core and Follow-up Phases)
yearsNilotinib
Overall Survival for Complete Study (Core and Follow-up Phases)NA ± NA
SecondaryProportion of Participants With Treatment-emergent Adverse Events During the Entire Study (Core and Follow-up Phases)

This measure summarizes the proportion of participants who experienced at least one treatment-emergent adverse event (TEAE) during the entire study period, including both core and follow-up phases. A TEAE was defined as an adverse event that began or worsened after the first dose of study treatment.

Time frame:
from the first dose through the end of the study (core and follow-up phases): including all visits up to the follow-up database lock (approximately 16 years)
Reported as:
Count of participants · Participants
Proportion of Participants With Treatment-emergent Adverse Events During the Entire Study (Core and Follow-up Phases)
ParticipantsNilotinib
Proportion of Participants With Treatment-emergent Adverse Events During the Entire Study (Core and Follow-up Phases)39

Adverse events

Collected over Adverse events were collected from first dose through the end of the study (core and follow-up phases), including all visits up to the follow-up database lock (approximately 16 years).. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Total Core0/41 (0%)10/41 (24.4%)39/41 (95.1%)
Total Follow up0/31 (0%)14/31 (45.2%)28/31 (90.3%)
Most frequent serious events
Showing 10 of 42
Most frequent serious events
EventTotal CoreTotal Follow up
ABDOMINAL PAINGastrointestinal disorders2/412/31
PYREXIAGeneral disorders2/412/31
CARDIAC FAILURECardiac disorders0/412/31
VERTIGOEar and labyrinth disorders0/412/31
MYOCARDIAL INFARCTIONCardiac disorders1/411/31
CARDIAC FAILURE CHRONICCardiac disorders0/411/31
CARDIAC FAILURE CONGESTIVECardiac disorders0/411/31
CARDIO-RESPIRATORY ARRESTCardiac disorders0/411/31
CORONARY ARTERY DISEASECardiac disorders0/411/31
PERICARDIAL EFFUSIONCardiac disorders0/411/31
Most frequent other events
Showing 10 of 254
Most frequent other events
EventTotal CoreTotal Follow up
CONSTIPATIONGastrointestinal disorders7/419/31
ALOPECIASkin and subcutaneous tissue disorders8/419/31
ABDOMINAL PAINGastrointestinal disorders11/418/31
ASTHENIAGeneral disorders11/412/31
HEADACHENervous system disorders11/415/31
PRURITUSSkin and subcutaneous tissue disorders11/415/31
DRY SKINSkin and subcutaneous tissue disorders8/418/31
FATIGUEGeneral disorders10/415/31
RASHSkin and subcutaneous tissue disorders10/416/31
OEDEMA PERIPHERALGeneral disorders8/417/31

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Nilotinib
Mean58 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)Nilotinib
Female19
Male22
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Nilotinib
Caucasian40
Black1
08

Study locations

10 sites
  • Novartis Investigative Site
    Helsinki, FIN-00029, Finland
  • Novartis Investigative Site
    Lyon, 69373, France
  • Novartis Investigative Site
    Munich, Bavaria 81377, Germany
  • Novartis Investigative Site
    Bad Saarow, 15526, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Hanover, 30625, Germany
  • Novartis Investigative Site
    Milan, MI 20133, Italy
  • Novartis Investigative Site
    Palma, Balearic Islands 07120, Spain
  • Novartis Investigative Site
    L'Hospitalet de Llobregat, Barcelona 08907, Spain
  • Novartis Investigative Site
    Valencia, Valencia 46009, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2008 to primary completion in Dec 2024, 195 months.

Results were first posted in Jan 2026, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2008
First posted
Sep 22, 2008
StartActual
Aug 29, 2008
Primary completionActual
Dec 18, 2024
CompletionActual
Dec 18, 2024
Results first posted
Jan 20, 2026
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00756509
Responsible party
Sponsor
First posted
Sep 22, 2008
Start date
Aug 29, 2008
Primary completion
Dec 18, 2024
Completion
Dec 18, 2024
Results posted
Jan 20, 2026
Last update
Jul 16, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nilotinib

Start the discussion